• LEVITY
  • Posts
  • LEVITY PODCAST #2 - Peter Ottsjö

LEVITY PODCAST #2 - Peter Ottsjö

”We could be some of the last people that have to die”

In this week’s newsletter

✅ Introduction to our second episode with tech journalist and author Peter Ottsjö. ✅ Detailed show notes.  ✅ Peter’s longevity gene. ✅ Learn more about rapamycin, senolytics and cellular reprogramming.✅ Who was Luigi Cornaro and what can we learn from the naked mole-rat?

”We could be some of the last people that have to die in what we today call a normal lifespan”

Hi everyone! As this second episode features me as the guest I had Patrick write the introduction. You can find links to the LEVITY podcast below. Enjoy (and please like, rate, subscribe - this will help us reach a bigger audience)!

/Peter

Longevity escape velocity, zombie cells, senolytica, mTOR, rapamycin and Yamanaka factors, whether these are familiar concepts or they are new to you, Peter Ottsjö, who is an author and a science and technology reporter at Ny Teknik and co-host of the LEVITY podcast, has written a book that explains them and connects them to a project that might be the greatest revolution in the history of humanity: the longevity revolution.

Not content with learning about the theory of longevity, Peter has also put what he has learnt into action. His goal is to live beyond 120 years, or, more precisely, his goal is to stay young forever, as is also the title of his book, Evigt Ung.

In this episode we will hear from Peter how he plans to accomplish this goal. The interview will take us from the history of ideas of longevity to the latest science and thereby provide a great base and overview of the topic. Peter has a great gift of explaining science and technology in a clear and vivid, and even fun way.

You can watch the second episode below or listen to it on Spotify, Apple Podcasts or other places, like PocketCasts. Please follow, like and subscribe! 🙏🏼 This will boost our chances of reaching a bigger audience.

Show notes

For those who want to dig deeper

Subscribe to keep reading

This content is free, but you must be subscribed to LEVITY to continue reading.

Already a subscriber?Sign In.Not now